ADC Therapeutics (NYSE: ADCT) revenue
ADC Therapeutics reported revenue of $81.4m for fiscal 2025, 14.9% more than in fiscal 2024 ($70.8m). Since fiscal 2022 its revenue has fallen by 61.2%, an average decline of 27.1% a year.
ADC Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 4 was fiscal 2022. The biggest drop was in fiscal 2023, −66.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $81.4m | +14.9% | −$121.5m | −149.3% |
| 2024 | $70.8m | +1.8% | −$130.7m | −184.4% |
| 2023 | $69.6m | −66.9% | −$166.0m | −238.6% |
| 2022 | $209.9m | — | −$123.3m | −58.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
ADC Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, ADC Therapeutics ranks 301st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; ADC Therapeutics, 14.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 299th | Arcturus Therapeutics | $82.0m | −46.1% |
| 300th | MeiraGTx | $81.4m | 144.6% |
| 301st | ADC Therapeutics | $81.4m | 14.9% |
| 302nd | ETON Pharmaceuticals | $80.0m | 104.9% |
| 303rd | Simulations Plus | $79.2m | 13.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of ADC Therapeutics
- How much revenue did ADC Therapeutics make in fiscal 2025?
- ADC Therapeutics reported revenue of $81.4m for fiscal 2025, compared with $70.8m in fiscal 2024.
- How much has the revenue of ADC Therapeutics fallen?
- Between fiscal 2022 and fiscal 2025 it went from $209.9m to $81.4m: 61.2% less, an average decline of 27.1% a year.
- What was the best year for revenue at ADC Therapeutics?
- Of its last 4 fiscal years, fiscal 2022, with $209.9m.
- Where does ADC Therapeutics rank in its sector by revenue?
- It ranks 301st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for ADC Therapeutics come from?
- From the annual report (Form 10-K) that ADC Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that ADC Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on ADC Therapeutics: the ADC Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.